Developing Biopharma Plays to Look at Now (STAB, MEIP, ABIO, AMPE, ZIVO, MREO)

Biopharmaceutical stocks have profitable catalysts in 2022. As a sector, the biopharma industry dropped in 2021 as COVID-19 declined. Now new opportunities are here.

Why It Matters To Investors

Here are catalysts for buying into biopharmaceutical stocks in 2022:

— The COVID-19 pandemic has settled into an endemic. Drug candidates remain profit makers but they focus now on non-hospitalized patients.

— Worldwide countries need to catch up with primary pandemic drugs from biopharmaceutical companies that pass clinical tests and are commercialized.

— Offshoot strains remain as variants globally. Ongoing vaccines are needed in low income countries to maintain reduced infection rates.

— Ongoing research trials continue for cancers, inflammatory pain and other rare diseases as the pandemic transitions into an endemic. 

— This is a $471.02 billion massive market by 2027, according to It’s growing at a CAGR of 9.1+%. 

Pandemic Transitions Into Lucrative Endemic For Biopharmaceuticals

This sector of stocks clinically tests the performance of commercially-potential candidate drugs. The goal is to address cure needs of diseases that range from COVID-19 and cancers to inflammatory pain management. 

Place STAB stock on your Watch List as it now progressing with next-gen R&D on its proprietary platform.

Here Are Biopharma Stocks With 2022 Catalysts

— Statera Biopharma, Inc. (NASDAQ: STAB) is advancing next-gen research activities based on proprietary compositions from its own STAT-200 platform. The result is that promising new compositions are being developed to treat a range of inflammatory diseases.

Michael K. Handley, president and CEO of the biopharmaceutical company,  says STAB’s clinical stage pipeline has the Company well positioned to achieve numerous milestones in 2022.

STAB Conducting Studies Of Drugs Treating Inflammatory Diseases

Investors should put STAB stock on their Watch Lists as biopharmaceutical companies performing clinical stage research are rising in valuation. Drug candidates to treat pain and inflammatory diseases are highly valuable in the commercial market. 

STAB is a clinical stage biopharmaceutical company. It targets autoimmune neutropenia/anemia emerging viruses. These include clinical programs for Crohn’s disease and pancreatic cancer. 

Biopharmaceutical Sector Stocks With 2022 Catalysts For Investors

—MEI Pharma, Inc. (NASDAQ: MEIP) is a late stage pharmaceutical company focused on advancing new therapies for cancer.  The Company is funding with $186 million in cash its R&D clinical research operations through calendar year 2023. It is focused on advancing oncology pipeline candidates.

MEI has received a $10 million milestone payment from Kyowa Kirin Co. by terms of a 2020 license agreement, development and a commercialization agreement. The payment was triggered by a fiscal year 2022 Phase 3 COASTAL lymphoma study. The US FDA granted the Company’s candidate orphan-drug designation for the treatment of lymphoma.

— ARCA Biopharma, Inc. (NASDAQ: ABIO) is an early stage biotechnology company with a market cap of $28 million. Analysts are concerned about its cash burn rate, but it has options. They include issuing new shares or taking on debt. In the midst of this, ABIO could have a successful drug candidate for commercialization.

For example, ABIO announced completion of enrollment in its Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. The Company anticipates reporting top line data from this clinical trial in Q1 2022. 

— Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on therapies and treatments for pain and inflammatory conditions from osteoarthritis. It has just presented in the California-based ROTH Conference to financial investors.

Its lead drug is Ampion™ which is backed by an extensive patent portfolio  offering property protection through 2037. It may be eligible for 12-year FDA market exclusivity as a novel biologic.

— ZIVO Bioscience, Inc. (NASDAQ: ZIVO) offers a new management team headed by John B Payne, president and CEO. This pharmaceutical company has numerous drug candidates in the therapeutic, nutritional and medicinal fields.

To investors, it offers a focus on developing algae technology. It is seeking to complete its up list to the NASDAQ trading exchange and a broader exposure to the sophisticated financial community. The company studies  bioactive compounds derived from proprietary algae cultures. It also seeks to develop natural bioactive compounds for us as dietary supplements. 

— Mereo BioPharma Group (NASDAQ: MREO) is a clinical stage biopharmaceutical company focused on the treatment of cancer and rare diseases. It has strengthened it board by adding Anne Hyland, who has more than 30 years of financial experience in the biopharmaceutical space.

The company has developed a portfolio of six clinical stage product candidates. Its lead candidate is anti-TIGIT and has advanced into a Phase 1b/2 basket study. It is designed to treat three tumor types: carcinomas, cervical and ovarian. MREO’s second oncology product has completed a Phase 1 study. A partner is expected to conduct a first half 2022 pediatric study for another leading drug candidate. 

Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at

Disclaimers: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall CGR. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by CGR., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, CGR., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated one thousand five hundred dollars via wire transfer per release by Crossroads to produce and syndicate content for STAB. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
Country: United States